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Conclusion: The net effect of ezetimibe/simvastatin is to inhibit cholesterol synthesis
and the absorption of phytosterols (in conjunction with cholesterol). Clinical relevance
and implications with respect to atherosclerosis development and progression warrant
further studies.
1008-184 The Effects of Pravastatin and Atorvastatin on Markers 
of Oxidant Stress In Vivo
Bonnie Ky, Megan L. Wolfe, Anne Burke, Philippe O. Szapary, Muredach P. Reilly, 
Jennifer B. Dykhouse, Leanne T. Bloedon, Garret A. FitzGerald, Daniel J. Rader, 
University of Pennsylvania School of Medicine, Philadelphia, PA
Treatment with inhibitors of 3-hydroxy-3methylglutaryl coenzyme reductase(statins)
decreases low density lipoprotein (LDL) cholesterol, but their effects on oxidative stress
are unclear.We performed a randomized, controlled clinical trial in which subjects
received pravastatin 40, atorvastatin 10, atorvastatin 80 or placebo therapy with the goal
of assessing the effects of statins on markers of oxidant stress. METHODS: 120 patients
(68 males and 52 females) between the ages of 21-80 with an LDL cholesterol between
130-220 mg/dl without known atherosclerotic disease, diabetes mellitus, chronic renal
insufficiency, or exposure to prior lipid lowering therapy were recruited. Patients were ran-
domized to one of the four arms and treated for 16 weeks. At baseline and 16 weeks,
plasma oxidized LDL was measured using a commercially available ELISA assay and uri-
nary isoprostanes were determined using GC/MS. RESULTS: After 16 weeks, reductions
in LDL cholesterol with statin therapy were as expected. With regards to changes in oxi-
dized LDL, pravastatin 40mg led to an 18.8% reduction, atorvastatin 10mg led to a 28%
reduction and atorvastatin 80mg led to a 32% reduction. In the placebo group, there was
a nonsignificant change in oxidized LDL over 16 weeks (3.65 %). However, there were no
significant changes in urinary isoprostane levels across all treatment arms. CONCLU-
SIONS: Pravastatin and atorvastatin led to statistically significant decreases in plasma
oxidized LDL concomitant with changes in LDL cholesterol, but did not lead to reductions
in urinary isoprostane excretion.
1008-185 Benefit of Statins in Secondary Prevention After Acute 
Myocardial Infarction: Evidence of a Class Effect
Zheng Zhou, Elham Rahme, Jack Tu, Karin Humphries, Mark Eisenberg, Michal 
Abrahamowicz, Peter Austin, Louise Pilote, Montreal General Hospital, Montreal, PQ, 
Canada, Institute for Clinical Evaluation Science, Toronto, ON, Canada
Background: Clinical trials have shown several statins to improve survival after acute
myocardial infarction (AMI). However whether all statins have a similar effect in reducing
recurrent AMI and death remains unclear. We conducted a population-based study to
assess whether a class effect exists among statins for secondary prevention. Methods:
A retrospective cohort study (1997~2002) was used to compare 5 statins based on the
hospital discharge and prescription claims databases from 3 provinces of Canada (Que-
bec, Ontario and British Columbia). The cohort consisted of patients > 65 years with a
first-recorded AMI since 1997. The effect of statin use on outcome was evaluated using a
Cox survival model adjusting for patient demographic and clinical characteristics as well
as specialty of treating physician, hospital type and the year of AMI. Switching, stopping
treatment and dosage change were also analysed. Result: A total of 18,637 statin users
were studied with a median follow-up of 2.5 years [atorvastatin (n=6420), pravastatin
(n=4480), simvastatin (n=5518), lovastatin (n=1736) and fluvastatin (n=483)]. Similar
baseline characteristics and statin usage patterns were found across different statin
groups and provinces. Compared to atorvastatin, the hazard ratios and 95% confidence
intervals for recurrent MI or death whichever occurred first revealed an equivalent effect
among statins: pravastatin 1.00 (0.90- 1.11), simvastatin 1.01 (0.91-1.12), lovastatin 1.09
(0.95-1.24) and fluvastatin 1.01(0.80-1.27). The conclusion remained unchanged when
studying all-cause mortality alone while treating recurrent MI as a time dependent covari-
ate. Censoring patients at switching or stopping treatment did not alter the results. Con-
clusion: Our results suggested that, despite the differences in their chemical structure
and metabolic properties, a beneficial class effect can be assumed for statins in the sec-
ondary prevention post AMI.
1008-186 Encapsulation of Pravastatin Tablets Produces Greater 
Low-Density Lipoprotein Cholesterol Lowering in 
Patients With Human Immunodeficiency Virus Infection 
Dyslipidemia Taking Protease Inhibitors
Matthew K. Ito, Victoria E. Aldridge, Jennifer J. Howard, Eric K. Gupta, Scott T. Johns, 
Joseph K. Wong, University of the Pacific, Stockton, CA, VA San Diego Healthcare 
System, San Diego, CA
Background: Dyslipidemia is well recognized in patients with Human Immunodeficiency
Virus (HIV) disease receiving antiretroviral therapy. Pravastatin is moderately effective at
reducing LDL cholesterol and has documented efficacy in reducing cardiovascular
events. Biotransformation of pravastatin occurs primarily by isomerization in the gut to a
relatively inactive (1/40 the reductase inhibitory activity) metabolite (SQ31,906). We have
shown that this biotransformation contributes to interindividual variability in the reduction
in LDL cholesterol. It is suggested that encapsulating or enteric coating pravastatin may
reduce this biotransformation and increase the efficacy of the drug.
Methods: We randomized 12 adult males with HIV to pravastatin 10 mg tablets either
encapsulated (placed within gel capsule with lactose) or non-encapsulated for 4 weeks
and were crossed-over following a 4 week washout.
Results: Lipid and pharmacokinetic parameters are shown in the table. Encapsulation of
pravastatin produced greater reductions in total (22% vs 12%, p=0.012) and LDL (25 %
vs 13%, p=0.021) cholesterol compared to non-encapsulation. The one hour post dose
ratio of plasma pravastatin to SQ31,906 were higher (2.2 vs 1.1, p=0.061) following
encapsulation compared to non-encapsulation. No differences in C-reactive protein (hs-
CRP) were noted.
Conclusion: Encapsulation of pravastatin significantly improves its LDL-lowering effi-
cacy by reducing biotransformation to SQ31,906.
1008-187 Effect of Pravastatin on Endothelial Function in Human 
Immunodeficiency Virus-Infected Persons on Protease 
Inhibitor-Containing Antiretroviral Combination Therapy
David Hurlimann, Jr., Remy Chenevard, Frank Ruschitzka, Sr., Jorg Muntwyler, Sr., 
Thomas Luscher, Sr., Georg Noll, Sr., Markus Flepp, Jr., Bruno Ledergerber, Sr., Rainer 
Weber, Sr., University Hospital Zurich, Zurich, Switzerland
Background: Antiretroviral combination therapy has altered cardiovascular risks and
manifestations in HIV-infected persons. Protease inhibitors in particular have been linked
to dyslipidemia, glucose intolerance, an increase in cardiovascular events and endothe-
lial dysfunction. Treatment of the pro-atherogenic lipid profile as well as improving endot-
helial function may be important for the long-term prognosis of these patients. The aim of
this study was to evaluate the effects of pravastatin on endothelial function and plasma
lipid profile.
Methods: 31 patients (mean age 45 ±9.3 years) with HIV-1 infection who were treated
with stable proteinase inhibitor-containing antiretroviral combination therapy for at least 4
months were randomly assigned to receive pravastatin 40mg daily or matching placebo
for 8 weeks in a double-blind cross-over fashion. Flow-mediated vasodilation (FMD) of
the brachial artery was assessed by high-resolution ultrasound at baseline and after
each treatment period, and plasma lipid levels were measured.
Results: Pravastatin significantly improved flow-mediated dilation compared to baseline
after 8 weeks treatment (3.2±1.6% vs. 2.3±1.0%, p=0.003). Further, improvement in
endothelial function was superior to placebo (3.2±1.6% vs. 2.5±1.2%, p=0.013). Total
cholesterol was lowered from 6.6±1.1 to 5.6±1.1mmol/l (-14.8%) p<0.0001) and LDL
from 3.7±0.9 to 3.1±0.9mmol/l (-16.3%) p=0.0003. Alterations in flow-mediated dilation
were inversely correlated to changes in LDL cholesterol (r=0.36, p=0.014). 
Conclusions: Our study demonstrates that pravastatin in HIV patients improves PI-con-
taining HAART associated endothelial dysfunction. The observed effects on the vascular
endothelium seem at least in part to be mediated by lowering LDL cholesterol. Thus,
pravastatin might hold the potential to improve prognosis in HIV infected patients with
protease inhibitor induced dyslipidemia.
1008-188 Trends in Use of Statins in Older Patients With Heart 
Failure
JoAnne M. Foody, Deron Galusha, Frederick A. Masoudi, Saif S. Rathore, Edward P. 
Havranek, Harlan M. Krumholz, Yale University School of Medicine, New Haven, CT
Background: Statin therapy improves outcomes in patients with ischemic cardiomyopathy
and may improve cardiac function and functional class in patients with idiopathic dilated
cardiomyopathy irrespective of serum cholesterol levels or atherosclerotic heart disease.
Little is known regarding trends in the use of statins in a population-based sample of
older patients with heart failure.
Methods and Results: In national cohorts of 39,477 and 39,405 older patients hospital-
ized between 1998-9 and 2000-1 respectively with heart failure, we assessed change in
rates of use of statins at discharge in patients surviving to discharge without contraindi-
cations to statins. Overall, 11.9% and 21.8% of patients were discharged in 1998-9 and
2000-1, respectively. While patients with prior history of PTCA or CABG were more likely
to receive these agents, as were those with elevated total cholesterol, women and the
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elderly (>/= 75 years of age) were consistently less likely to receive statins on discharge.
Conclusions: Statin use was low irrespective of CAD status and total cholesterol levels in
older patients with heart failure. These results emphasize the importance of continued
efforts to improve secondary prevention in older patients with HF and ischemic heart dis-
ease.
1008-189 Atorvastatin Therapy Reduces Markers of Myocardial 
Damage After Percutaneous Coronary Interventions? 
Preliminary Data From a Randomized Study
Giuseppe Patti, Vincenzo Pasceri, Annunziata Nusca, Christian Pristipino, Antonio 
Granatelli, Francesco Pelliccia, Andrea D'Ambrosio, Marco Miglionico, Bruno Pironi, 
Massimo Chello, Giuseppe Richichi, Germano Di Sciascio, Campus Bio-Medico 
University, Rome, Italy, S. Filippo Neri Hospital, Rome, Italy
Background. Peri-procedural myocardial damage after percutaneous coronary interven-
tion has been associated with higher risk of adverse events during the follow-up. Obser-
vational studies have suggested that patients (pts) pre-treated with statins have a lower
risk of peri-procedural myocardial damage after percutaneous revascularization. Aim of
our study was to confirm this hypothesis in a randomized pilot study (120 pts planned).
Methods. We present results from the first 53 enrolled pts (62±4 yrs, diabetics 23%), all
with stable angina. Pts, waiting for elective percutaneous coronary intervention, have
been randomized to atorvastatin (40 mg/day, N=26, Group A) or placebo (N=27, Group
B) from 7 days before the procedure. Myoglobin, Troponin I and CK-MB isoenzyme levels
were measured before the procedure, after 6 and 24 hours.
Results. All pts received coronary stent implantation with 100% of procedural success;
1.4 stents/pt were implanted. An increase above the threshold value in CK-MB values
was observed in 17% of pts of Group B and in 8 % of those of Group A (P=0.13), in
Troponin I levels respectively in 56% and 34% (P=0.10) and in Myoglobin values in 44%
and 23% (P=0.09). The post-procedural increase in Troponin I levels from baseline was
0.37±0.4 ng/ml in pts of Group B vs 0.14±0.3 ng/ml in those of Group A (P=0.05).
Conclusions. Preliminary data from this randomized study suggest that pre-treatment
with high doses of atorvastatin may reduce the occurrence of peri-procedural myocardial
damage after percutaneous coronary intervention with stenting. Complete data from this
study should be available at the moment of presentation.
1008-190 Amlodipine/Atorvastatin Single Pill Dual Therapy 
Improves Goal Attainment in the Treatment of 
Concomitant Hypertension and Dyslipidemia: The 
Gemini Study
Roy Blank, James LaSalle, Russell Reeves, Beth Anne Piper, Franklin Sun, Presbyterian 
Healthcare Associates of Monroe, Monroe, NC
Background: Hypertension (HTN) and dyslipidemia (DYS) are prevalent and up to 50%
of patients with one have the other. Having both HTN and DYS results in a high risk of
cardiovascular disease (CVD). Furthermore, hypertensive and dyslipidemic goal attain-
ment is poor, with less than 10% of patients achieving both goals. The management of
these patients should therefore focus on achieving goals for both blood pressure and low-
density lipoprotein cholesterol (LDL-C) to diminish CVD risk.
Methods: Gemini is a 14-week, open-label, non-comparative, multicenter trial designed
to evaluate the efficacy and safety of atorvastatin/amlodipine single pill as initial or add-
on (integrated) therapy in the treatment of concomitant HTN and DYS. All patients had
concomitant HTN and DYS and qualified for drug therapy. In addition to lifestyle modifica-
tion, eight dosage strengths of amlodipine/atorvastatin single pill (5/10 mg, 10/10 mg, 5/
20 mg, 10/20 mg, 5/40 mg, 10/40 mg, 5/80 mg, and 10/80 mg) were titrated to improve
blood pressure and lipid control. The primary efficacy assessment was the percentage of
patients attaining both their blood pressure (Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure VI) and LDL-C (National
Cholesterol Education Program Adult Treatment Panel III) goals at endpoint.
Results: A total of 1220 patients received study medication. At baseline, mean (± SD)
systolic/diastolic blood pressure was 146.6 ± 11.0/87.9 ± 8.6 mmHg and mean LDL-C
concentration was 152.7 ± 33.2 mg/dL. At endpoint, 57.7% of patients reached both their
blood pressure and LDL-C therapeutic goals. Fifty-eight patients (4.8%) discontinued due
to adverse events (AEs). The most common AEs were respiratory tract infection (11.9%),
peripheral edema (8.8%), headache (5.4%), and myalgia (4.2%).
Conclusion: These data demonstrate that atorvastatin/amlodipine single pill is an effec-
tive and well-tolerated treatment for coexisting HTN and DYS, which helps patients better
achieve their goals for both conditions than reported historically. Atorvastatin/amlodipine
single pill should improve management of total CVD risk in patients with concomitant
HTN and DYS.
1008-191 Statin Therapy Is Associated With a 67 Percent 
Reduction in Mortality in Patients With Severe Chronic 
Heart Failure: Results From the Placebo Arm of the 
ENABLE Study
Olga Milo, Isaac Kobrin, Aline Frey, Loic Perchenet, Edo Kaluski, Nir Uriel, Alex Blatt, Zvi 
Vered, Gad Cotter, Assaf-Harofeh Medical Center, Zerifin, Israel, Actelion LTD, Allschwil, 
Switzerland
Recent small studies have demonstrated that statins therapy is correlated with improved
outcome in patients with chronic heart failure.
Methods: We examined the effect of statin therapy on the outcome of 1,000 patients with
chronic CHF NYHA IIIb or IV and echocardiographic ejection fraction < 35% enrolled in
the placebo arm of the ENABLE study. Statin therapy allocation was not randomized and
decided by each investigator, Statin therapy included simvastatin, atrovastatin, pravasta-
tin, lovastatin, cerivastatin and fluvastatin in different doses.
Results: Statin treatment was related to a 67% reduction in the risk of all cause mortality
(p<0.0001, Figure) but was not correlated with re-admissions due to heart failure. In the
present cohort statin treatment was the strongest predictor of outcome and remained an
independnt predictor in multivariate analysis.
Conclusions: Although retrospective, the results of the present study demonstrate a
strong correlation between all cause mortality and statin treatment in patients with heart
failure. This ovservation requires verification by a large prospective randomized study.
1008-192 Atorvastatin Affects Thrombosis/Fibrinolysis System 
During the Acute Phase of Unstable Angina
Dimitris Tousoulis, Maria Kotsopoulou, Charalambos A. Antoniades, Erini Bosinakou, 
Costas Tentolouris, Kyriaki Marinou, Charalambos Vlachopoulos, Emmanuel 
Vavuranakis, Christos Pitsavos, Christodoulos Stefanadis, Hippokration Hospital, Athens 
University, Athens, Greece
Background: Evidence suggest that lipid-lowering treatment with statins reduces mortal-
ity and morbitity in patients with coronary artery disease. The effects of lipid-lowering
treatment during the early phase of the acute coronary syndromes are unknown. In this
study we investigated the effect of atorvastatin treatment on plasma levels of tissue plas-
minogen activator (tPA), von Willebrand factor (vWF) and factors V (fV) and VII (fVII), in
patients with unstable angina.
Methods: Forty-six patients (34 males 12 females, aged 64+/-8 years old) with unstable
ungina, were randomly divided into 2 groups and received atorvastatin 10 mg/day (n=23,
ATR group) or no statin treatment (n=23, ATR group) for 6 weeks during and after admis-
sion. Plasma levels of tPA, vWF, fV and fVII were measured at baseline, at 1 week and at
6 weeks after the admission. Levels of the above thrombotic markers were determined by
ELISA. All values are expressed as means+/-SEM.
Results: At baseline, levels of tPA, vWF, fV and fVII were not significantly different
between ATR (10.03±0.78 ng/ml, 107±6.5%, 125±7.8% and 92±4.4%) and the control
group (10.8±1.0 ng/ml, 109.3±9.2%, 126±8.1% and 90.7±6.7%, p=NS for all). After 1
week, serum levels of tPA, vWF, fV and fVII were significantly increased in control group
(13.3±1.3 ng/ml p<0.01, 127±8.5% p<0.05, 152±7.4% p<0.001 and 104±8.6% p<0.05
respectively, compared to baseline). This increase was prevented in ATR group
(12.7±1.8ng/ml, 125±9.7%, 134±5.8% and 109±7.7% respectively, p=NS compared to
baseline). However, at 6 weeks, plasma levels of tPA, vWF, fV and fVII returned to their
baseline values in both ATR group (11.2±0.9ng/ml, 91.6±8.9%, 125.3±7.8% and
94.8±6.7% respectively, p=NS for all compared to baseline) and control group
(11.4±0.95ng/ml, 98.8±10.6%, 118±6.9% and 114±31%, p=NS for all compared to base-
line).
Conclusions: During the first week of treatment, atorvastatin decreases the levels of fac-
tors V, VII, von Willebrand factor and tissue plasminogen activator in patients with unsta-
ble angina. These findings suggest that early administration of atorvastatin in patients
with unstable ungina, may be beneficial by affecting the thrombotic/fibrinolytic process.
Trends in Statin Use in Older HF Survivors
1998-9
N =28,854
%
2000-1
N =27,025
%
Overall Use 11.9 21.8
Age >/= 75 years 8.5 17.5
Prior PTCA or CABG 23.7 38.4
Total cholesterol >/= 200 mg/dL 22.6 33.5
